JP7324710B2 - 肺癌の処置のための抗ｐｄ－１抗体 - Google Patents

肺癌の処置のための抗ｐｄ－１抗体 Download PDF

Info

Publication number
JP7324710B2
JP7324710B2 JP2019545324A JP2019545324A JP7324710B2 JP 7324710 B2 JP7324710 B2 JP 7324710B2 JP 2019545324 A JP2019545324 A JP 2019545324A JP 2019545324 A JP2019545324 A JP 2019545324A JP 7324710 B2 JP7324710 B2 JP 7324710B2
Authority
JP
Japan
Prior art keywords
antibody
tumor
patient
treatment
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019545324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020508317A (ja
JP2020508317A5 (enExample
Inventor
ペトラ・リーチェル
イザレル・ロウィ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2020508317A publication Critical patent/JP2020508317A/ja
Publication of JP2020508317A5 publication Critical patent/JP2020508317A5/ja
Priority to JP2022037781A priority Critical patent/JP7384949B2/ja
Application granted granted Critical
Publication of JP7324710B2 publication Critical patent/JP7324710B2/ja
Priority to JP2023190525A priority patent/JP7656012B2/ja
Priority to JP2025044340A priority patent/JP2025098103A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019545324A 2017-02-21 2018-02-20 肺癌の処置のための抗ｐｄ－１抗体 Active JP7324710B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022037781A JP7384949B2 (ja) 2017-02-21 2022-03-11 肺癌の処置のための抗ｐｄ－１抗体
JP2023190525A JP7656012B2 (ja) 2017-02-21 2023-11-08 肺癌の処置のための抗ｐｄ－１抗体
JP2025044340A JP2025098103A (ja) 2017-02-21 2025-03-19 肺癌の処置のための抗ｐｄ－１抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762461672P 2017-02-21 2017-02-21
US62/461,672 2017-02-21
US201762595190P 2017-12-06 2017-12-06
US62/595,190 2017-12-06
PCT/US2018/018747 WO2018156494A1 (en) 2017-02-21 2018-02-20 Anti-pd-1 antibodies for treatment of lung cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022037781A Division JP7384949B2 (ja) 2017-02-21 2022-03-11 肺癌の処置のための抗ｐｄ－１抗体

Publications (3)

Publication Number Publication Date
JP2020508317A JP2020508317A (ja) 2020-03-19
JP2020508317A5 JP2020508317A5 (enExample) 2021-07-26
JP7324710B2 true JP7324710B2 (ja) 2023-08-10

Family

ID=61628468

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019545324A Active JP7324710B2 (ja) 2017-02-21 2018-02-20 肺癌の処置のための抗ｐｄ－１抗体
JP2022037781A Active JP7384949B2 (ja) 2017-02-21 2022-03-11 肺癌の処置のための抗ｐｄ－１抗体
JP2023190525A Active JP7656012B2 (ja) 2017-02-21 2023-11-08 肺癌の処置のための抗ｐｄ－１抗体
JP2025044340A Pending JP2025098103A (ja) 2017-02-21 2025-03-19 肺癌の処置のための抗ｐｄ－１抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022037781A Active JP7384949B2 (ja) 2017-02-21 2022-03-11 肺癌の処置のための抗ｐｄ－１抗体
JP2023190525A Active JP7656012B2 (ja) 2017-02-21 2023-11-08 肺癌の処置のための抗ｐｄ－１抗体
JP2025044340A Pending JP2025098103A (ja) 2017-02-21 2025-03-19 肺癌の処置のための抗ｐｄ－１抗体

Country Status (12)

Country Link
US (3) US11292842B2 (enExample)
EP (1) EP3585812A1 (enExample)
JP (4) JP7324710B2 (enExample)
KR (2) KR102628557B1 (enExample)
CN (2) CN110536905B (enExample)
AU (2) AU2018225102B2 (enExample)
CA (1) CA3054289A1 (enExample)
IL (3) IL268479B2 (enExample)
MA (1) MA47604A (enExample)
MX (2) MX2019009772A (enExample)
WO (1) WO2018156494A1 (enExample)
ZA (1) ZA201905051B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160053301A1 (en) 2014-08-22 2016-02-25 Clearfork Bioscience, Inc. Methods for quantitative genetic analysis of cell free dna
ES2992478T3 (es) 2015-08-11 2024-12-12 Wuxi Biologics Ireland Ltd Nuevos anticuerpos anti-PD-1
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
MX2019009772A (es) * 2017-02-21 2019-12-02 Regeneron Pharma Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
EP3700561A1 (en) * 2017-10-27 2020-09-02 Statens Serum Institut A polygene influenza vaccine
MA53651A (fr) 2018-09-19 2021-07-28 Alpine Immune Sciences Inc Méthodes et utilisations de protéines de fusion de variant cd80 et constructions associées
US12473364B2 (en) 2018-11-14 2025-11-18 Regeneron Pharmaceuticals, Inc. Intralesional administration of PD-1 inhibitors for treating skin cancer
TW202043273A (zh) * 2019-01-21 2020-12-01 法商賽諾菲公司 用於晚期實性瘤癌症之治療性ｒｎａ
JP2022521800A (ja) * 2019-02-28 2022-04-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 皮膚がんを治療するためのｐｄ－１阻害剤の投与
MA55204A (fr) 2019-03-06 2022-01-12 Regeneron Pharma Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
KR20220115803A (ko) * 2019-12-13 2022-08-18 삼성바이오에피스 주식회사 안정한 항-pd-1 항체 약제학적 제제
CN113244385A (zh) * 2020-02-07 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗恶性肿瘤中的用途
JP2023517671A (ja) * 2020-03-13 2023-04-26 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ６－チオ－ｄＧ、チェックポイント阻害剤および放射線療法を使用するがんの逐次処置
WO2023185720A1 (zh) * 2022-03-28 2023-10-05 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
EP4598960A1 (en) * 2022-10-05 2025-08-13 Chulalongkorn University Monoclonal antibodies against human programmed cell death protein 1 (pd-1)
WO2025030110A1 (en) * 2023-08-02 2025-02-06 Sensei Biotherapeutics, Inc. Cancer therapies targeting vista as monotherapy or in combination with anti-pd1 antibody to treat cancer
WO2025159618A1 (ko) 2024-01-24 2025-07-31 주식회사 엘지에너지솔루션 전극탭 용접장치 및 전극탭 용접방법
WO2025207705A1 (en) 2024-03-26 2025-10-02 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
WO2025213154A1 (en) 2024-04-05 2025-10-09 Amgen Inc. Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505125A (ja) 2014-01-23 2017-02-16 リジェネロン・ファーマシューティカルズ・インコーポレ Ｐｄ−１に対するヒト抗体

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
IL147972A0 (en) 1999-08-23 2002-09-12 Dana Farber Cancer Inst Inc Ge Pd-1, a receptor for b7-4 and uses therefor
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
ES2729974T3 (es) 2003-01-23 2019-11-07 Ono Pharmaceutical Co Anticuerpo específico de PD-1 y CD3 humanas
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
CN103059138B (zh) 2005-05-09 2015-10-28 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
NZ564592A (en) 2005-07-01 2011-11-25 Medarex Inc Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
AU2008275589B2 (en) 2007-07-12 2013-11-21 Gitr, Inc. Combination therapies employing GITR binding molecules
WO2009030285A1 (en) 2007-09-07 2009-03-12 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
MX2011002252A (es) 2008-08-25 2011-06-24 Amplimmune Inc Composiciones de antagonistas del pd-1 y metodos de uso.
MX2011005853A (es) 2008-12-09 2011-08-04 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
RU2646139C1 (ru) 2009-09-03 2018-03-01 Мерк Шарп И Доум Корп. Анти-gitr-антитела
AU2010324757C1 (en) 2009-11-24 2018-05-17 Medimmune Limited Targeted binding agents against B7-H1
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
WO2013014668A1 (en) 2011-07-24 2013-01-31 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
MY193562A (en) 2011-08-01 2022-10-19 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2013166500A1 (en) 2012-05-04 2013-11-07 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
WO2014018498A1 (en) 2012-07-23 2014-01-30 Meadwestvaco Calmar, Inc. Aerosol actuators, devices, and methods of making and using the same
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2015030929A1 (en) 2013-08-30 2015-03-05 Ebay, Inc. Keyword bid optimization for text ads
WO2015088930A1 (en) 2013-12-10 2015-06-18 Merck Sharp & Dohme Corp. Immunohistochemical proximity assay for pd-1 positive cells and pd-ligand positive cells in tumor tissue
HRP20240939T1 (hr) 2013-12-17 2024-10-25 Genentech, Inc. Anti-cd3 protutijela i metode uporabe
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
KR102870759B1 (ko) * 2014-05-15 2025-10-15 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
HUE053857T2 (hu) 2014-05-28 2021-07-28 Agenus Inc Anti-GITR antitestek és eljárások azok elõállítására
RS59643B1 (sr) 2014-06-06 2020-01-31 Bristol Myers Squibb Co Antitela na glukokortikoidom indukovani receptor faktora nekroze tumora (gitr) i njihova primena
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
KR102482295B1 (ko) 2014-06-19 2022-12-30 리제너론 파마슈티칼스 인코포레이티드 인간화 프로그램화 세포 사멸 1 유전자를 가지는 비인간 동물
KR20170101925A (ko) * 2014-12-02 2017-09-06 셀진 코포레이션 병용 요법
DK3254110T3 (da) 2015-02-03 2020-05-18 Ventana Med Syst Inc Histokemisk test til vurdering af ekspression af programmeret død-ligand 1 (pd-l1)
US10336824B2 (en) 2015-03-13 2019-07-02 Cytomx Therapeutics, Inc. Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof
SMT202000442T1 (it) * 2015-04-17 2020-09-10 Bristol Myers Squibb Co Composizioni comprendenti una combinazione di ipilimumab e nivolumab
HUE051815T2 (hu) * 2015-05-12 2021-03-29 Hoffmann La Roche Terápiás és diagnosztikai eljárások rákra
US20180155429A1 (en) * 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
AU2017224843A1 (en) 2016-02-25 2018-08-23 Cell Medica Switzerland Ag Binding members to PD-L1
EP3548515B1 (en) 2016-12-01 2026-01-21 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
MX2019009772A (es) * 2017-02-21 2019-12-02 Regeneron Pharma Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
US20240270849A1 (en) * 2022-10-03 2024-08-15 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with bispecific egfr xcd28 antibodies alone or in combination with anti-pd-1 antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505125A (ja) 2014-01-23 2017-02-16 リジェネロン・ファーマシューティカルズ・インコーポレ Ｐｄ−１に対するヒト抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ａｎｎａｌｓ ｏｆ Ｏｎｃｏｌｏｇｙ， ２０１４年， Ｖｏｌ．２５， Ｓｕｐｐｌ．３， ｉｉｉ２７－３９

Also Published As

Publication number Publication date
IL268479A (en) 2019-09-26
AU2018225102B2 (en) 2024-11-14
JP2025098103A (ja) 2025-07-01
EP3585812A1 (en) 2020-01-01
JP7656012B2 (ja) 2025-04-02
JP7384949B2 (ja) 2023-11-21
US20240209090A1 (en) 2024-06-27
US11926668B2 (en) 2024-03-12
IL308805A (en) 2024-01-01
KR20240011262A (ko) 2024-01-25
MX2024000780A (es) 2024-02-06
RU2019129506A (ru) 2021-03-23
US20220281979A1 (en) 2022-09-08
MX2019009772A (es) 2019-12-02
CN110536905B (zh) 2023-10-27
WO2018156494A1 (en) 2018-08-30
CN117442719A (zh) 2024-01-26
IL321717A (en) 2025-08-01
KR20190120792A (ko) 2019-10-24
JP2020508317A (ja) 2020-03-19
CA3054289A1 (en) 2018-08-30
AU2025201018A1 (en) 2025-03-06
ZA201905051B (en) 2025-06-25
MA47604A (fr) 2020-01-01
US11292842B2 (en) 2022-04-05
KR102628557B1 (ko) 2024-01-29
AU2018225102A1 (en) 2019-09-05
US20200010550A1 (en) 2020-01-09
IL308805B2 (en) 2025-12-01
IL268479B2 (en) 2024-06-01
JP2022078265A (ja) 2022-05-24
JP2024016192A (ja) 2024-02-06
IL268479B1 (en) 2024-02-01
RU2019129506A3 (enExample) 2021-07-02
CN110536905A (zh) 2019-12-03
IL308805B1 (en) 2025-08-01

Similar Documents

Publication Publication Date Title
JP7384949B2 (ja) 肺癌の処置のための抗ｐｄ－１抗体
JP7624033B2 (ja) Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法
RU2771759C2 (ru) Антитела против pd-1 для лечения рака легких
EA045900B1 (ru) Комбинация антител против pd-1 и облучения для лечения злокачественной опухоли

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210519

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211207

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230731

R150 Certificate of patent or registration of utility model

Ref document number: 7324710

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150